{
    "organizations": [],
    "uuid": "b88a6455d864bafd097ca8dcad9a418fcbeedc8b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-cidara-reports-positive-topline-re/brief-cidara-reports-positive-topline-results-from-phase-2-strive-trial-of-lead-antifungal-rezafungin-idUSASC09SR7",
    "ord_in_thread": 0,
    "title": "BRIEF-Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 42 AM / Updated 3 minutes ago BRIEF-Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin Reuters Staff March 19 (Reuters) - Cidara Therapeutics Inc: * CIDARA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 STRIVE TRIAL OF LEAD ANTIFUNGAL REZAFUNGIN * CIDARA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 STRIVE TRIAL OF LEAD ANTIFUNGAL REZAFUNGIN * CIDARA THERAPEUTICS INC - ‍PHASE 3 STUDIES FOR BOTH TREATMENT AND PREVENTION ON TRACK TO START MID-2018​ * CIDARA THERAPEUTICS INC - PHASE 3 STUDIES FOR BOTH TREATMENT AND PREVENTION ON TRACK TO START MID-2018 * CIDARA THERAPEUTICS - ‍FAVORABLE SAFETY,TOLERABILITY,EFFICACY OBSERVED IN ONCE-WEEKLY ECHINOCANDIN FOR DIFFICULT-TO-TREAT INVASIVE FUNGAL INFECTIONS​ * CIDARA THERAPEUTICS INC - ‍STRIVE MET ALL OF ITS PRIMARY OBJECTIVES​ * CIDARA THERAPEUTICS INC - ‍THERE WERE NO CONCERNING TRENDS IN ADVERSE EVENTS OBSERVED​ * CIDARA THERAPEUTICS-THERE WERE 2 SERIOUS ADVERSE EVENTS POSSIBLY RELATED TO STUDY DRUG: ONE IN GROUP 2, ONE IN GROUP 3; BOTH PATIENTS FULLY RECOVERED​ * CIDARA THERAPEUTICS INC - ‍ PHASE 3 RESPECT PROPHYLAXIS TRIAL EXPECTED TO PRODUCE AN INTERIM FUTILITY READ-OUT IN 2019, PROVIDE TOPLINE RESULTS IN 2020​ Source text for Eikon: Further company coverage:",
    "published": "2018-03-19T13:42:00.000+02:00",
    "crawled": "2018-03-19T13:47:17.060+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "report",
        "positive",
        "topline",
        "result",
        "phase",
        "strive",
        "trial",
        "lead",
        "antifungal",
        "rezafungin",
        "reuters",
        "staff",
        "march",
        "reuters",
        "cidara",
        "therapeutic",
        "inc",
        "cidara",
        "therapeutic",
        "report",
        "positive",
        "topline",
        "result",
        "phase",
        "strive",
        "trial",
        "lead",
        "antifungal",
        "rezafungin",
        "cidara",
        "therapeutic",
        "report",
        "positive",
        "topline",
        "result",
        "phase",
        "strive",
        "trial",
        "lead",
        "antifungal",
        "rezafungin",
        "cidara",
        "therapeutic",
        "inc",
        "study",
        "treatment",
        "prevention",
        "track",
        "start",
        "cidara",
        "therapeutic",
        "inc",
        "phase",
        "study",
        "treatment",
        "prevention",
        "track",
        "start",
        "cidara",
        "therapeutic",
        "safety",
        "tolerability",
        "efficacy",
        "observed",
        "echinocandin",
        "invasive",
        "fungal",
        "cidara",
        "therapeutic",
        "inc",
        "met",
        "primary",
        "cidara",
        "therapeutic",
        "inc",
        "concerning",
        "trend",
        "adverse",
        "event",
        "cidara",
        "serious",
        "adverse",
        "event",
        "possibly",
        "related",
        "study",
        "drug",
        "one",
        "group",
        "one",
        "group",
        "patient",
        "fully",
        "cidara",
        "therapeutic",
        "inc",
        "phase",
        "respect",
        "prophylaxis",
        "trial",
        "expected",
        "produce",
        "interim",
        "futility",
        "provide",
        "topline",
        "result",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}